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in Option B+ program in Kigali, Rwanda
The Kabeho Study
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Placidie Mugwaneza, MDc, Laura Guay, MDa,b, Gilles F. Ndayisaba, MDa,
Emily A. Bobrow, PhD, MPHa, Anita Asiimwe, MD, MPHd, Lynne M. Mofenson, MDa
Abstract
Lifelong antiretroviral therapy (ART) provision to all pregnant HIV-positive women (“Option B+”) has been recommended by the World
HealthOrganization since 2013, but there remain limited data on the effects ofOptionB+on long-termHIV-free survival in breastfeeding
HIV-exposed infants. The Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) study enrolled HIV-
positive women from the third trimester of pregnancy to 2 weeks postpartum in 14 heath facilities implementing Option B+ in Kigali,
Rwanda. Mother–child pairs in the longitudinal observational cohort were followed until 24 months postpartum, with HIV diagnostic
testing at 6 weeks, and 9, 18 and 24months. The Kaplan–Meier method was used to estimate HIV transmission, survival, and HIV-free
survival through 24months.We enrolled 608HIV-positivewomen in 2013–2014; birth outcomedatawere available for 600womenand
597 live-born infants. By 6 weeks, 11 infants had died and 3 infants had confirmed HIV infection (0.5% transmission; 95% confidence
interval [CI] 0.2–1.6). At 9months, therewere 9 additional deaths and2 new infections (cumulative transmission 0.9%, 95%CI 0.4–2.2).
At 18months, therewere6additional deathsandnonew infant infections.At24months, therewerenoadditional child deathsand1new
infection (cumulative 2.2%, 95%CI 0.7–7.0), for an overall 24-month HIV-free survival of 93.2% (95%CI 89.5–95.6). Low transmission
rates and high HIV-free survival at 24 months were achieved in breastfeeding infants of HIV-positive mothers receiving universal ART in
urban health facilities in Rwanda, though vigilance on maintaining viral suppression for ART-experienced women is needed.
Abbreviations: ART = antiretroviral therapy, DBS = dried blood spot, eMTCT = Elimination of Mother-to-Child Transmission,
Kabeho = The Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV Study, MTCT = mother-to-child
transmission, PCR= polymerase chain reaction, PMTCT= prevention of mother-to-child transmission, VL= viral load, WHO=World
Health Organization.
Keywords: HIV-free survival, lifelong antiretroviral therapy, option B+, prevention of mother-to-child transmission, Rwanda
1. Introduction
Elimination ofmother-to-childHIV transmission is a global public
health priority.[1] In 2013, theWorldHealthOrganization (WHO)
recommended antiretroviral therapy (ART) administration to all
HIV-positive women during pregnancy and breastfeeding,
regardless of CD4 cell count or clinical stage, for prevention of
mother-to-child transmission (PMTCT), with ART duration
through at least cessation of breastfeeding. In generalized HIV
epidemic settings, ART was to be given for life (referred to as
“Option B+”).[2] This was broadened in 2015 to recommend
lifelong ART for all HIV-positive individuals, including pregnant/
breastfeeding women, regardless of clinical/immune status.[3]
Although there are promising results on program effectiveness for
prevention of early infant HIV transmission, there is a paucity of
data on the long-term effectiveness of these guidelines through the
duration of breastfeeding and on 24-month HIV-free survival.
In April 2012, the Government of Rwanda began national
implementation of Option B+ as well as an innovative infant
feeding counseling and support program with modules specifi-
cally focused on optimizing PMTCT for HIV-positive women.
This was part of the Rwanda National Strategy for the
Elimination of Mother-to-Child Transmission (eMTCT), with
a target to reduce HIV transmission to 2% at 18 months
postpartum by 2015.[4]
The Kigali Antiretroviral and Breastfeeding Assessment for the
Elimination of HIV (Kabeho) study was a longitudinal
observational study conducted between 2013 and 2016 among
HIV-positive women participating in the national PMTCT
program in Kigali, Rwanda, that was designed to evaluate the
effectiveness of the Rwandan eMTCT program, including
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evaluation of 24-month HIV-free infant survival. Further details
on enrollment of the cohort are provided elsewhere.[5]
2. Methods
Between April 2013 and January 2014, 608HIV-positive women
were enrolled from 14 high-volume (defined as caring for >50
HIV-positive pregnant women/year) health facilities in Kigali.
Women were eligible if they had documented HIV infection, were
in the third trimester of pregnancy or within 2 weeks
postdelivery, enrolled in the PMTCT program during antenatal
care at 1 of the study sites, planned to remain in the Kigali area
after delivery, and were able and willing to provide informed
consent for herself and her infant. All women were expected to
have initiated lifelong ART for this pregnancy if they were not
already on treatment (in line with Option B+ national policy);
however, being on treatment was not a criterion for study
inclusion. Per ethical guidelines in Rwanda, informed consent
was also required from parents of unmarried pregnant women
aged less than 18 years. The final 24-month study visits were
completed in May 2016.
Women and their infants were followed at monthly clinic visits
that coincided with follow-up visits required for the national
PMTCT program. During study visits, demographics, HIV and
ART-related history, ART adherence (assessed by self-reported
recall of doses missed in the past 3 days), ART side effects, and
nutritional and infant feeding information were collected.
Medical and laboratory information were also abstracted from
the relevant facility records. Data were reviewed for completeness
and quality, and entered in the study database using SurveyCTO
Version 2.10 (Dobility, Cambridge, MA). All study staff received
training on the protocol, data collection and the protection of
human subjects in research.
HIV infection status was determined from routine test results
performed using national procedures and algorithms for infant
HIV diagnosis: HIV DNA polymerase chain reaction (PCR) at 6
weeks, and initial rapid HIV antibody testing at age 9, 18, and 24
months, followed by a confirmatory HIV DNA PCR test if
antibody positive. Children with an initial HIV DNA PCR
positive test result had a confirmatory PCR performed; HIV
infection was diagnosed in infants with a confirmed positive PCR
assay. Additionally, a dried blood spot (DBS) specimen was taken
at the birth visit to retrospectively determine the infants’ HIV
status at birth. Children diagnosed with HIV infection were
referred to HIV care and treatment services. Maternal viral load
(VL) was evaluated by HIV RNA PCR at the time of enrollment
and within 2 weeks of delivery, at 18 and 24 months. PCR testing
for VL (HIV RNA) and early infant diagnosis (HIV DNA) were
conducted at the Rwanda National Reference Laboratory using
Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test quanti-
tative test (v2.0) and Roche COBAS Ampliprep/COBAS TaqMan
HIV-1 qualitative test (v2.0), respectively.
Ethical approvals were obtained from the Rwandan National
Ethics Committee, the Rwanda National Health Research
Committee, and the George Washington University Institutional
Review Board. Participants provided written informed consent
prior to the conduct of study procedures. The protocol is
registered at clinicaltrials.gov (NCT02295800).
2.1. Statistical analysis
A sample size of 608 permitted an estimate of the HIV-free
survival at 18 and 24months achieving a 3% precision level. This
was based on the assumption that 91.9% of infants would be
alive and HIV-free at 18 months, using an expected 3% HIV
infection rate and an infant mortality rate in Kigali of 55 per 1000
live births, with a 2-sided 95% confidence interval (CI) around
the observed proportion and a design effect of 1.6.[6,7]
Descriptive summary statistics were calculated for predictor
and outcome variables of interest using frequencies and
percentages for categorical variables. Medians and interquartile
ranges (IQRs) are presented for continuous variables. Select
demographic and clinical characteristics were presented sepa-
rately for the womenwhose children becameHIV-infected during
the study period. Undetectable HIV VL is defined as <20copies/
mL, which was the lower limit of detection of the laboratory
assay. Kaplan–Meier curves were used to graphically represent
mortality, transmission and the combined effect of HIV-free
survival up to 24 months. Transmission data for children were
censored at the date of their first HIV-positive blood test. All
statistical tests were 2-sided and the level of statistical significance
was set at 0.05. Statistical analyses were conducted using SAS 9.4
(Cary, NC).
3. Results
Of 721 eligible women, 608 women were enrolled in the Kabeho
study, 84.8% during the third trimester of pregnancy and 15.2%
within 2 weeks postpartum. Birth outcome data were available
for 600 HIV-positive women and their 597 live-born infants,
including 7 sets of twins; there were 10 stillbirths (1.6%) (Fig. 1).
At the end of the 2-year postpartum follow-up period, retention
among children in the study was 75.9% (n=453). Out of 37
women who had a study visit around 18 months, but did not
attend their 24-month study visit, 22 women did come to the
facility for their routine clinic visit at approximately 24 months.
Primary reasons for loss to follow-up after delivery were transfers
from Kabeho sites to nonstudy sites for clinical care (n=39) and
participant withdrawal (n=20).
Median age was 29.0 years; most women (79.0%) were
married/cohabiting (Table 1). Educational attainment was low:
16.2% of women had no education and 60.3% attended primary
school only. Only 2.2% had a home with private toilet and 6.7%
had piped water. Nearly three-quarters of study women (73.5%)
knew their HIV status prior to the current pregnancy, for a
median time of 65.4 months (IQR 32.5, 99.5). Only 26.5% of
women were first diagnosed with HIV during the current
pregnancy. Disclosure of HIV status to a partner was common;
81.7%of women had disclosed to their partner, and 82.2%knew
the HIV status of the father (50.3% HIV-positive, 31.9% HIV-
uninfected, and 17.8% of unknown status). Median ART
duration was 13.8 months; 63.5% of women (n=381) were
already on ART at their first ANC visit. The most common ART
regimen was tenofovir/lamivudine/efavirenz, corresponding with
Rwandan policy at the time. Although all study participants were
enrolled in the PMTCT program, 14 women were not on ART at
study entry, 3 of whom enrolled postpartum. Reasons for
nonreceipt of ART included provider postponing ART initiation
until serum creatinine test results were returned (n=4), women
who had previously been lost to follow-up (n=4), drug stock-out
(n=1), refusal to take ART (n=1), interrupted treatment (n=1),
and not yet initiated without specific reason cited (n=3).
At enrollment, 52.5% had undetectable plasma VL (<20
copies/mL) and 84.7% had HIV RNA <1000copies/mL
(Table 1). Similar to the enrollment results, 55.3% had
undetectable plasma VL and 88.4% had HIV RNA <1000
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copies/mL at delivery. 24-month VL results were only available
for 70.3% of study women who had delivered. Of these, 78.2%
had undetectable plasma VL and 91.2% had HIV RNA <1000
copies/mL.
Thirty-six women reported having had a previous child who
was HIV-infected with the most recent transmissions occurring in
2012; 3 of these women had 2 previous HIV-infected children.
The majority of these previous infections (25/39) occurred when
women were not yet aware of their HIV-positive status. Only 1
was on lifelong ART prior to the index pregnancy and 4 were
started on ART for life during that pregnancy. Of the 35 women
with VL data available around the time of delivery of the study
infant, 31 women had a VL of <1000copies/mL. One of these
women transmitted to a study infant; she had detectable viral
load at all study measurements.
3.1. Pregnancy outcome and maternal and infant mortality
Most women had a vaginal delivery (80.5%) and delivered at a
health facility (96.5%). Maternal complications at delivery were
reported for 13.8% of women (n=83), with the most common
being prolonged labor (n=38), maternal hemorrhage (n=10),
fetal distress (n=9), and breech delivery (n=7). Overall, there
were 3 maternal deaths, for a 24-month maternal mortality rate
of 0.5%; 1 woman died after giving birth, 1 died a week after
giving birth, and 1 died when her child was over age 18 months.
There were 10 stillbirths (1.6%). Of the 597 live births, 51.8%
were female (Table 2). Birth defects were identified in 1.3%
infants (n=8): 3 with polydactyly, 3 lingual frenulum, 1
imperforate anus, and 1 congenital heart disease. Only 1.3%
infants (n=8) were preterm (<37 weeks gestation), and 5.6%
(n=33) had a birth weight below 2500 grams, as measured
within 7 days of birth. Almost all infants received 6-week
nevirapine prophylaxis (96.4%), with 80.1% initiating nevira-
pine immediately after birth. Of the 589 infants surviving more
than 2 days after birth, most (97.6%) were breastfed; exclusive
breastfeeding was reported by 88.0% at age 1 month and 61.2%
at 5 to 6 months.
3.2. Infant mortality
The Kaplan–Meier cumulative probability of child mortality is
shown in Figure 2 and Table 3. There were 26 child deaths,
including 3 infants who died within 2 hours of birth and 5 others
within 2 days. Estimated 24-month mortality was 4.8% (95%CI
3.3–6.9). Reported causes of infant mortality included diarrhea
(n=1), respiratory infection (n=3), tuberculosis (n=1), other
infections (n=2), birth asphyxia (n=2), anemia (n=1), fever (n=
1), and malnutrition (n=1). Causes of child death were unknown
for 14 children. Data on HIV infection status at last visit prior to
death or birth DBS was available for 65.4% (n=17) live born
infants who died; none were found to be HIV-infected.
3.3. HIV transmission
The Kaplan–Meier cumulative probability of HIV transmission is
shown in Figure 2 and Table 3. A total of 6 HIV-infected infants
were identified in the cohort, with an estimated cumulative 24-
month transmission rate of 2.2% (95% CI 0.7–7.0). At 6 weeks,
1 infant was confirmed to be HIV-infected with a positive HIV
DNA PCR test, for an estimated 6-week cumulative transmission
rate of 0.5% (95% CI 0.2–1.6). Testing at 9 months resulted in
confirmed HIV infection in 2 additional infants, for an estimated
9-month cumulative transmission rate of 0.9% (95% CI 0.4–
2.2). At 18 months, no new HIV infections were identified. At 24
months, 1 additional infant was confirmed as HIV-infected.
DBS specimens collected at birth were retrospectively tested; 2
of the 6 (33.3%) HIV-infected infants had an HIV DNA PCR
positive test at birth, reflecting an in utero infection rate of 0.3%.
One of the infants with a positive birth HIV DNA PCR was
confirmed as HIV-infected at age 9 months. This infant had an
initial 6-week positive HIV DNA PCR, and was started on ART
Women enrolled in the cohort = 608
Women at delivery = 600
Live-born infants born = 597
Children at ~6 weeks = 577 (96.6%)
Children at ~9 months = 547 (91.6%)
Children at ~18 months = 514 (86.1 %)
Children at ~ 24 months = 453 (75.9%)
Women terminated before delivery = 8
Sets of twins  =7
Sllbirths =10
Live-born infants who died within 2 days of birth = 8 
Infants who died between >2 days and 8 weeks = 3
Transferred out of Kabeho sites = 2
Parcipant withdrawal = 3
LTFU = 4
Infants who died between >8 weeks and 10.5 months = 9
Transferred out of Kabeho sites = 11
LTFU=10
Infants who died between 10.5 and 19.5 months = 6
Transferred out of Kabeho sites = 21
LTFU = 6
Transferred out of Kabeho sites = 5
Parcipant withdrawal = 9
LTFU = 47
Figure 1. Follow-up of Kabeho study infants. Children remaining in the cohort following delivery and through 24months of age at HIV testing time points of 6 weeks,
9, 18, and 24 months. Children who died, transferred out of study facilities or whose caregivers withdrew their consent were terminated. Other infants who were
expected at these time points but did not return for any further study visits were considered lost to follow-up (LTFU).
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pending the confirmatory HIV PCR test result, per Rwandan
national guidelines. When 2 subsequent confirmatory test results
came back negative, ART was discontinued, and the child was
retested at age 9 months, whenHIV infection was confirmed. The
other infant with a retrospective positive birth PCR was
confirmed as HIV-infected following the 6-week test.
Table 4 presents the characteristics of the 6 women who
transmittedHIV to their infants, including 1who reported having
had a previous child who was HIV-infected. All 6 transmitting
mothers enrolled into the study during pregnancy (third
trimester). The duration on ART at delivery for the transmitting
womenvaried from2.5 to91.1months; 3womenhadbeenonART
prior to the current pregnancy, all for >2 years. Only 1 woman
reported missing 1 pill when 3-day recall was assessed at
enrollment; all other transmitting women reported 100% adher-
ence at enrollment and delivery. Despite reported good ART
adherence, 5 of 5 women tested at enrollment had detectable VL,
ranging from577 to272,000copies/mL, and5of5women testedat
delivery had detectable VL, ranging from 558 to 290,000copies/
mL. At 18 months, 3 of 5 women tested still had detectable VL
(24,500–49,000copies/mL), andat 24months, 3of 5women tested
hadVL>1000copies/mL (7,220–172,000copies/mL). Postpartum
ARTregimen changeswerenoted in2 of the 6 transmittingwomen;
the other 4 women were consistently on their original tenofovir/
lamivudine/efavirenz ART regimen. All 6 women reported
exclusive breastfeeding through age 3 months (with range up to
7 months), and any breastfeeding for up to 19 months.
All 6 of the HIV-infected children were initiated on ART with
abacavir/lamivudine/lopinavir-ritonavir, and all were alive at 24
months.
3.4. HIV-free survival
The Kaplan–Meier cumulative probability of HIV-free survival
is shown in Figure 2. Excluding stillbirths, at 6 weeks there were
11 infant deaths and 3 infected infants, with an HIV-free survival
of 97.6% (95% CI 96.0–98.6). At 9 months, there were 9
additional infant deaths and 2 additional infected children,
resulting in an HIV-free survival of 95.6% (95% CI 93.6–97.0).
At 18 months, there were 6 additional deaths, and no additional
HIV-infected children, resulting in anHIV-free survival of 94.4%
(95% CI 92.1–96.0). At 24 months, there were no additional
child deaths, and 1 new infection, for an overall 24-month HIV-
free survival of 93.2% (95%CI 89.5–95.6) (Table 3). Of the 415
children testing HIV-negative around 24months, 11 (2.7%)were
still breastfeeding and remained at risk of HIV infection.
4. Discussion
The 24-month HIV transmission rate of 2.2% that we report in
the Kabeho study is among the lowest, and HIV-free survival rate
Table 1
Characteristics of women enrolled in the Kabeho study.
Maternal and household characteristics
of women who delivered (n=600) Value
Enrolled during pregnancy, n (%) 509 (84.8%)
Enrolled postpartum, n (%) 91 (15.2%)
Age at enrollment (y), median (IQR) 29.0 (25.0–34.0)
Married/co-habiting, n (%) 474 (79.0%)
Gravidity (n=600), median (IQR) 3.0 (2.0–4.0)
Education, n (%)
No education 97 (16.2%)
Attended primary school 362 (60.3%)
Attended secondary school and above 141 (23.5%)
Household size, median (IQR) (n=600) 3.0 (2.0–4.0)
Private toilet n (%) 13 (2.2%)
Water piped in house, n (%) 40 (6.7%)
Time of HIV diagnosis
During current pregnancy 159 (26.5%)
Before current pregnancy 441 (73.5%)
Duration of antiretroviral therapy overall (mo),
(n=586), median (IQR)
13.8 (3.0–49.9)
Started prior to pregnancy: duration (mo),
(n=381), median (IQR)
36.0 (16.1–68.4)
Started during pregnancy: duration (mo),
(n=205), median (IQR)
2.4 (1.3–3.7)
Antiretroviral regimen at enrollment, n (%)
Tenofovir/lamivudine/efavirenz 341 (56.8%)
Tenofovir/lamivudine/nevirapine 136 (22.7%)
Zidovudine/lamivudine/nevirapine 63 (10.5%)
Other regimen
∗
47 (7.9%)
None 14 (2.3%)
Maternal laboratory data
Enrollment CD4 count (cells/mm3)
(n=533), median (IQR)
467.0 (346.0–612.0)
Enrollment viral load (copies/mL)
(n=596), median (IQR)
<20 (<20.0–220.0)
Undetectable (<20 copies/mL) 313 (52.5%)
<1000 copies/mL 505 (84.7%)
≥1000 copies/mL 91 (15.3%)
Delivery viral load (copies/mL)
(n=550), median (IQR)
<20 (<20.0–110.0)
Undetectable (<20 copies/mL) 304 (55.3%)
<1000 copies/mL 486 (88.4%)
≥1000 copies/mL 64 (11.6%)
18-month viral load (copies/mL)
(n=426), median (IQR)
<20 (<20.0–<20.0)
Undetectable (<20 copies/mL) 332 (77.9%)
<1000 copies/mL 387 (90.8%)
≥1000 copies/mL 39 (9.2%)
24-month viral load (copies/mL)
(n=422), median (IQR)
<20 (<20.0–<20.0)
Undetectable (<20 copies/mL) 330 (78.2%)
<1000 copies/mL 385 (91.2%)
≥1000 copies/mL 37 (8.8%)
∗
Of the other regimens, 9 contained a protease inhibitor (lopinavir/ritonavir).
Table 2
Characteristics of infants enrolled in the Kabeho study.
Pregnancy outcome (n=607), n (%)
Stillbirth 10 (1.6%)
Live-born 597 (98.4%)
Infant gender female, n (%) 309 (51.8%)
Infants born as twins 7 (1.2%)
Gestational age at birth (wk) (n=593)
<37, n (%) 8 (1.3%)
≥37, n (%) 585 (98.7%)
Infant birth weight (kilogram) (n=593), median (IQR) 3.2 (2.9–3.6)
<2.5, n (%) 33 (5.6%)
≥2.5, n (%) 560 (94.4%)
Infant antiretroviral prophylaxis (n=589)
None, n (%) 21 (3.6%)
Initiated nevirapine prophylaxis 568 (96.4%)
Timing of infant antiretroviral prophylaxis initiation (n=567)
Immediately after birth, n (%) 454 (80.1%)
Day 1, n (%) 88 (15.5%)
Day 2–3, n (%) 11 (1.9%)
Day >3, n (%) 14 (2.5%)
Gill et al. Medicine (2017) 96:51 Medicine
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of 93.2% is among the highest, reported in a real-world clinic
setting in breastfeeding HIV-positive women in Africa to date.
These results contrast with a household survey conducted in
Rwanda in 2009, when ART was given only to pregnant women
with CD4 <350cells/mm3, with zidovudine/single-dose nevira-
pine prophylaxis for those with higher CD4 cell count;
transmission at 9 to 24 months was 4.0% with estimated
HIV-free survival 91.9%.[6] A survey conducted by the Ministry
of Health in July 2015, which sampled sites throughout Rwanda,
found a 1.8% mother-to-child transmission (MTCT) rate at 18
months nationally and a 1.3%MTCT rate at 18months in the 14
Kabeho study sites.[8] The long-term low transmission and high
survival rates in the current study occurred despite the health
facilities serving women living in significant poverty, with 77%
having no education or only attending primary school and few
women living in homes with a toilet or piped water, and despite
prolonged duration of breastfeeding.
Although low transmission rates have been reported in the
context of clinical trials, generally these studies had stopped
maternal ART and breastfeeding at 6 months postpartum; for
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Figure 2. Kaplan–Meier cumulative probabilities of child mortality (blue), HIV transmission (red) and HIV-free survival (yellow) up to age 24 months.
Table 3
Infant infection status and mortality from Kaplan–Meier estimates.
Time of infection/death
Number of events
in interval (n)
∗
Cumulative number
of events (n)
Transmission/death
rate % (95% CI)
Cumulative survival
% (95% CI)
Birth†,‡ (n=597)
Infection (n=517)x 2 2 0.3 (0.08–1.3) 99.7 (98.7–99.9)
Death (within 2 d) 8 8 1.4 (0.7–2.7) 98.7 (97.3–99.3)
6 wk (n=577)
Infection (n=556) 1 3 0.5 (0.2–1.6) 99.5 (98.4–99.6)
Death >2 d–8 wk 3 11 1.9 (1.0–3.4) 98·1 (96.7–99.0)
9 mo (n=547)
Infection (n=512) 2 5 0.9 (0.4–2.2) 99.1 (97.8–99.6)
Death >8 wk–10.5 mo 9 20 3.5 (2.3–5.4) 96.5 (94.6–97.7)
18 mo (n=514)
Infection (n=454) 0 5 0.9 (0.4–2.2) 99.1 (97.8–99.6)
Death 10.5–19.5 mo 6 26 4.8 (3.3–6.9) 95.3 (93.1–96.8)
24 mo (n=453)
Infection (n=416) 1 6 2.2 (0.7–7.0) 97.8 (93.0–99.4)
Death 19.5–<28.0 mo 0 26 4.8 (3.3–6.9) 95.3 (93.1–96.8)
24-month HIV-free survival 6.8 (4.4–10.6) 93.2 (89.5–95.6)
ART = antiretroviral therapy, DBS = dried blood spot
∗
Two infected infants tested positive at 0 days, and the other 4 tested positive at 6 weeks, 9.7 months, 9.9 months, and 25.5 months. Three infants died within 2hours of birth, 1 within the first 24 hours of birth,
2 at 1 day, 2 at 2 days, and the other 18 died at 9 days, 5.1 weeks, 2.0 months, 2.2 months, 2.5 months, 3.1 months, 3.4 months, 4.4 months, 5.1 months, 6.0 months, 7.4 months, 9.4 months, 11.5 months,
11.8 months, 13.4 months, 18.6 months, 18.7 months, and 19.2 months.
† One infant who was antibody positive and HIV DNA PCR positive at 9 months was retrospectively found to have a positive DBS at birth. This child had a positive HIV DNA PCR at 6 weeks and was started on ART,
but when 2 confirmatory PCR tests came back negative, ART was discontinued. The child was retested at age 9 months when infection was confirmed.
‡ DBS retrospective testing.
x The n’s listed after infection indicate the number of children tested at each time point. However, we only excluded children from the denominator of the Kaplan–Meier estimate following death, HIV infection or
their last HIV test. For example, if a child was not tested at 9 months but had a negative test at 18 months, we still included them in the denominator at 9 months.
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example, in the Botswana Mma Bana trial, 24-month HIV
transmission was 1.1%, but median breastfeeding duration was
only 5.8 months and ART was provided only through 6 months
postpartum in women with CD4 cell count >200cells/mm3.[9]
The PROMISE trial is the only clinical trial with provision of
maternal ART during prolonged breastfeeding; transmission at
age 2 weeks with antepartum ART was 0.6%, similar to our
study, and postnatal transmission between 2 weeks and 24
months with postnatal maternal ART was 0.6%, giving a
cumulative infection rate of 1.2%.[10,11]
Transmission rates in observational studies in clinical settings
have generally been higher: in a prospective observational study
of 279 breastfeeding HIV-positive women on ART in Zambia,
transmission was 4.1% (95% CI 2.2–7.6) at 18 months; in a
study of 311 HIV-positive breastfeeding women on ART in
Malawi, transmission was 3.2% (95%CI 1.0–5.4) at 24 months;
and in a large nationally representative cohort of HIV-exposed
infants whowereHIVDNAPCRnegative at age 4 to 8weeks and
followed prospectively in South Africa when universal maternal
ART was recommended, cumulative 18-month transmission was
4.3%.[12–14] Similarly, a recent systematic review of 18 studies
evaluating HIV-free survival among breastfed infants of HIV-
positive women on ART reported pooled estimates of 12-month
and 24-month HIV-free survival of 89.8% (95% CI 86.5–93.2)
and 85.8% (95% CI 81.4–90.1), respectively.[15] The substantial
proportion of women on ART prior to pregnancy and with
suppressed VL may have contributed to the high effectiveness of
PMTCT in our study; approximately 64% of women were
already receiving ART at the time of their first antenatal care visit.
One of the hypothesized benefits of lifelong treatment is
protection against transmission in subsequent pregnancies, which
is supported by our data. Likewise, in a study of 298 women in
Cameroon, in which 51% of women were receiving ART prior to
pregnancy, 12-month HIV transmission was 1.2%.[16]
However, half of the transmissions occurred in women with
long durations of ART (2 to over 7 years). Two out of 3 of these
women had a VL >200,000copies/mL at study enrollment and
continued to have high VL throughout the 2-year follow-up
period. We had reported previously that HIV-positive pregnant
women in the Kabeho study who had received ART >36 months
(thus received ART preconception) had higher rates of detectable
virus at enrollment comparedwith womenwho had been onART
between 4 and 36 months.[5] Other studies have also found that a
significant minority of women, who conceived while receiving
ART, experienced viral rebound postpartum, which could be
associated with increased risk of mother-to-child transmis-
Table 4
Characteristics of transmitting mothers.
Transmitting mother #1 #2 #3 #4 #5 #6
Infant HIV test result timing
Positive birth HIV PCR
(retrospectively tested)
No Yes No No Yes No
Age at HIV-positive diagnosis 6 wk 6 wk 9 mo 9 mo 9 mo
∗
24 mo
Demographics
Maternal age, y 30 22 42 23 19 32
Marital status Married/Co-hab. Married/Co-hab. Married/Co-hab. Married/Co-hab. Never married Married/Co-hab.
Education Some primary Some primary Completed primary Completed primary No schooling Some primary
Gravidity (n) 3 2 5 2 1 4
HIV history
Disclosure Partner and someone else Partner only Partner and
someone else
Partner and
someone else
Someone other
than partner
Someone other
than partner
Paternal HIV status HIV-infected HIV-infected HIV-infected Do not know Do not know HIV-infected
Prior HIV-infected child Yes (1 of 2 children) No No No Not applicable No
Previous ARV for PMTCT AZT/sdNVP/tail prophylaxis
for previous 2 pregnancies
No On triple ARV prophylaxis
(Option B) for 3 previous
pregnancies
No Not applicable Started on ART
for life (Option B+)
during previous
pregnancy
Enrollment CD4, cells/mm3 570 596 383 528 610 178
Median time on ART at delivery, mo 28.8 6.1 33.7 2.5 2.7 91.1
Maternal viral load, copies/mL
Enrollment 272,000 2,000 577 Not available 2,350 202,000
Delivery 3,640 34,700 Not available 12,100 558 290,000
18 mo 33,500 24,500 <20 Not available <20 49,000
24 mo 23,600 25 7220 Not available <20 172,000
ART regimens at specific time points
Enrollment TDF/3TC/EFV TDF/3TC/EFV TDF/3TC/NVP TDF/3TC/EFV TDF/3TC/EFV D4T/3TC/EFV
6 wk TDF/3TC/EFV TDF/3TC/EFV TDF/3TC/NVP TDF/3TC/EFV TDF/3TC/EFV D4T/3TC/EFV
9 mo TDF/3TC/EFV TDF/3TC/EFV NO ARV TDF/3TC/EFV TDF/3TC/EFV TDF/3TC/EFV
18 mo TDF/3TC/EFV TDF/3TC/EFV AZT/3TC/ATV Not available TDF/3TC/EFV TDF/3TC/EFV
24 mo TDF/3TC/EFV TDF/3TC/EFV AZT/3TC/ATV Not available TDF/3TC/EFV TDF/3TC/EFV
Breast-feeding duration
Exclusive breast-feeding, mo 5 mo 4 mo 5 mo 3 mo 4 mo 7 mo
Any breast-feeding, mo 19 mo 18 mo Not BF at 9 mo 16 mo (last visit) 8 mo 18 mo
Maternal morbidity
Mother ever hospitalized No No No No No No
Mother died No No No No No No
Infant characteristics
Birth weight, kg 3.5 3.5 3.6 3.7 3.0 3.0
Received infant nevirapine
prophylaxis
Yes Yes Yes Yes Yes Yes
Mode of delivery Vaginal delivery Scheduled cesarean section Vaginal delivery Emergency cesarean section Vaginal delivery Vaginal delivery
3TC= lamivudine, ART= antiretroviral therapy, ARV= antiretroviral, ATV= atazanavir, AZT= zidovudine, D4T= stavudine, EFV= efavirenz, NVP=nevirapine, PMTCT=prevention of mother-to-child
transmission, sdNVP= single-dose nevirapine, TDF= tenofovir.
∗
This infant had an initial 6-week positive HIV DNA PCR, and was started on ART pending the confirmatory HIV PCR test result. When 2 confirmatory test results came back negative, ART was discontinued, and
the infant was retested at age 9 months, when HIV infection was confirmed. This infant also had a retrospective positive birth HIV DNA PCR.
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sion.[17] These data support the importance of VL monitoring
during pregnancy and breastfeeding, and adherence counseling.
Rwandan guidelines for management of individuals with VL
>1000copies/mL includes 2 repeat measurements at 3-month
intervals, additional adherence counseling and referral for clinical
consultation regarding need for second-line therapy if results do
not improve, but these may not be consistently implemented.
In our study, 5 of 6 infections (83.3%) occurred by 9 months
postpartum; 2 of these were in utero infections, 3 transmissions
were due to breastfeeding and the infection at 6 weeks was either
the result of intrapartum or early breastfeeding transmission.
Most infant deaths (20/26, 76.9%) also occurred by 9 months
postpartum. In the South African cohort discussed above, 81%of
overall transmission and 56%of postnatal transmission occurred
by 6 months postpartum, with 68% of postnatal transmission by
9 months.[14] Thus, the first 6 to 9 months of life appear to be a
particularly critical period for follow-up of HIV-exposed infants.
Mortality among live-born HIV-exposed infants in our study
was 4.4% (26/597) at 24 months. This is unchanged from a study
in Rwanda comparing mortality among HIV-exposed to HIV-
unexposed children between 2007 and 2008, when maternal
treatment was based onCD4 cell count andwomen not eligible for
treatment received prophylaxis with zidovudine/single-dose nevi-
rapine. In that study, the cumulative riskof death at age 2 yearswas
4.2% (95% CI 2.2–3.9) among HIV-exposed children compared
with1.5%(95%CI0.7–1.8) amongHIV-nonexposed children.[18]
Other studies have reported elevated rates of infant mortality
among HIV-exposed but uninfected infants, including those born
to mothers who were receiving ART.[19] These data suggest that
maternal ART and healthier mothers may not fully eliminate this
increasedmortality risk inHIV-exposed infants. Further research is
needed to better understand the underlying mechanisms for these
differences in mortality. Survival of the few known HIV-infected
infants in our cohort was excellent; all were rapidly linked to care
and initiated on ART, with 100% 24-month survival.
Limitations of our study include residual transmission risk
from the 11 infants still breastfeeding following the 24-month
HIV test and lack of HIV status among the 10 stillbirths in our
cohort, which could decrease our estimate of HIV-free survival. If
we assume all stillbirths were HIV-infected, the “worst case”
scenario for 24-month HIV-free survival would be 91.6% (95%
CI 87.9–94.3). There may have been underreporting of delivery
complications and birth defects, as they are based on data from
chart review. We also do not have final 24-month transmission
outcomes for the 67 mother–infant pairs who were lost to follow-
up as well as for those others who withdrew from the study or
transferred their care (n=51). We know at least some of the
womenwho did not present for the 24-month study visit were still
attending clinic; if they are considered, the percentage retained
after 24 months is nearly 80%. The substantial number of
women in this study who defaulted or transferred to another
facility highlight the importance of maintaining continuity of care
in highly mobile populations. There were also missing data on
causes of infant and child death for approximately half of the
infants who died. Finally, the Kabeho study includes a
representative sample of HIV-positive women and their new-
borns in urban Kigali only, and only those participating in
PMTCT programs in the highest volume sites in Kigali. The
sampling method of including in the study all clinics with 50 or
more HIV-exposed deliveries a year minimized bias, as women in
the study sites had an equal chance of being selected.
In summary, extremely low transmission and high HIV-free
survival and few maternal or infant adverse events were observed
with implementation of Option B+ in urban Rwanda, which may
be due in part to the high proportion of women who were
receiving ART prior to the current pregnancy. Our data strongly
support the current WHO recommendations for universal ART,
and suggest that the goal of eMTCT is possible with universal
implementation of treatment for all individuals and with
continued vigilance on maintaining viral suppression in those
on ART.
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